Company profile

Aiforia

Pathology & Laboratory Diagnostics

Company profile

About Aiforia

Aiforia Technologies is a digital pathology company that transforms pathology image analysis through artificial intelligence, enabling better care for each patient. The company equips pathologists and scientists in clinical, pre-clinical, and academic laboratories with powerful deep learning AI and cloud-based technology designed to increase the speed, accuracy, and consistency of analyzing large and complex medical images, especially in pathology. Aiforia's comprehensive portfolio includes CE-IVD marked Clinical Suites for breast, lung, prostate, gastric, and colorectal cancers, offering fully automated case-centric workflows that enhance diagnostic accuracy and productivity. These solutions provide AI-driven image analysis, standardized scoring, and automated reporting to achieve objective, quantitative, and explainable results. The company's research solutions offer study-centric workflows and pathology image analysis applications that cater to all research areas, empowering pathologists and scientists to make discoveries while automating repetitive tasks within GLP frameworks. At the core of Aiforia's offering is Aiforia® Create, a versatile cloud-based tool for developing deep learning AI models for image analysis in digital pathology. Its collaborative working environment allows multiple users to work together in real time from anywhere in the world, with an intuitive user interface that enables fast adoption even without prior AI experience. Aiforia's solutions integrate with existing laboratory infrastructure and are deployed in clinical settings worldwide, serving pathology laboratories, research institutions, pharmaceutical companies, and veterinary diagnostic labs.

Company description Aiforia official website

Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Aiforia?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • Breast cancer
  • Colorectal cancer
  • Gastric cancer
  • Helicobacter pylori
  • Lung cancer
  • Lymph node metastasis
  • Prostate cancer

Who it serves

  • Academic labs
  • Clinical diagnostic labs
  • Pathology laboratories
  • Pharmaceutical companies
  • Research institutions
  • Veterinary diagnostic labs

Deployment & integration

Cloud Saas deployment with recorded integration context.

Geographic context

MarketsEEA · EU · Global (RUO/PSO)
Company sourceOfficial website

Company milestones

Platform expansion

Announced next generation CE-IVD marked Prostate Cancer Biopsy AI solution. Expanded clinical suite portfolio across multiple cancer types.

Partnerships

Recorded partners

  • Mayo Clinic
  • University of Bern

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

Aiforia® Breast Cancer Suite

AI-powered histological grading and IHC marker assessment for breast cancer diagnostics

Software · Cloud SaaSCompany source

Aiforia® Colon Suite

AI solutions for colorectal cancer diagnostics and recurrence prediction

Software · Cloud SaaSCompany source

Aiforia® Colorectal Cancer QuantCRC

AI-powered recurrence prediction for colorectal cancer treatment decisions

Software · Cloud SaaSCompany source

Aiforia® Create

Cloud-based AI development tool for building deep learning models in digital pathology

Platform · Cloud SaaSCompany source

Aiforia® Gastric Suite

AI detection of gastric cancer and Helicobacter pylori in whole slide images

Software · Cloud SaaSCompany source

Aiforia® Lung Cancer Suite

AI-driven PD-L1 scoring for lung cancer to reduce errors and standardize assessments

Software · Cloud SaaSCompany source

Aiforia® Lymph Node Metastasis

AI detection and quantification of colorectal cancer metastases in lymph nodes

Software · Cloud SaaSCompany source

Aiforia® Prostate Cancer Suite

Next-generation AI solution for comprehensive prostate needle biopsy analysis and reporting

Software · Cloud SaaSCompany source

Aiforia® Research Solutions

Fully automated study-centric workflows for pathology image analysis in research

Platform · Cloud SaaSCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

Increased speed, accuracy, and consistency

Analyzing large and complex medical images in pathology

Enhanced diagnostic workflow efficiency

Comprehensive analysis and reporting of biopsies

Objective, quantitative, and explainable results

AI-driven image analysis and standardized scoring

Mayo Clinic

Development and validation of Colorectal Cancer QuantCRC for recurrence prediction

University of Bern

Development of Lymph Node Metastasis AI model for colorectal cancer detection

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

No active leadership profiles are currently listed.

06 · Company updates

Updates from Aiforia

Recent articles published on Aiforia's official website.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

No HAIC coverage is currently linked to this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Pathology & Laboratory Diagnostics

Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon